

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61B	A2	(11) International Publication Number: WO 95/28124 (43) International Publication Date: 26 October 1995 (26.10.95)
(21) International Application Number: PCT/US95/03259 (22) International Filing Date: 15 March 1995 (15.03.95) (30) Priority Data: 08/226,006 8 April 1994 (08.04.94) US		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TI, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARPO patent (KE, MW, SD, SZ, UG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(71) Applicant: ATRIX LABORATORIES, INC. (US/US); 2579 Midpoint Drive, Fort Collins, CO 80525 (US). (72) Inventors: DUNN, Richard, L.; 5021 Kitchell Way, Fort Collins, CO 80524 (US). YEWEY, Gerald, L.; Apartment 606, 451 Boardwalk Drive, Fort Collins, CO 80525 (US). SOUTHLAND, Jeffrey, L.; 2042 Custer Drive, Fort Collins, CO 80525 (US). URHEIM, John, E.; 5417 Taylor Lane, Fort Collins, CO 80525 (US). (74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Weiler & Schmidt, 3100 Northwest Center, 90 South 7th Street, Minneapolis, MN 55402 (US).		
(54) Title: AN ADJUNCTIVE POLYMER SYSTEM FOR USE WITH MEDICAL DEVICE (57) Abstract <p>A medical device which is a surgically implantable device coated with an adjunctive polymer system. The adjunctive polymer system forms a solid matrix when introduced into a human or animal body. The adjunctive polymer system can contain a drug or a medicament which is released over time from the solid matrix. The adjunctive polymer system contacts body tissue into which the surgically implantable device is implanted.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MN	Martinique
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Greece	MG	Niger
BE	Belgium	GR	Greece	ML	Netherlands
BF	Burkina Faso	HU	Hungary	MO	Norway
BG	Bulgaria	IE	Ireland	MZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sadah
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovakia
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Slovenia
CM	Cameroon	LK	Sri Lanka	TP	Senegal
CN	China	LU	Luxembourg	TG	Chad
CZ	Czechoslovakia	LV	Lviv	TJ	Togo
CZ	Czech Republic	MC	Monaco	TT	Tajikistan
DE	Germany	MD	Republic of Moldova	UA	Trinidad and Tobago
DK	Dominican	MG	Madagascar	UB	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Guinea				

AN ADJUNCTIVE POLYMER
SYSTEM FOR USE WITH MEDICAL DEVICE

Background of the Invention

Medical devices have been developed for a large number of applications in humans and animals.

10 These include wound closure devices such as sutures, staples and clips; wound covering devices such as bandages, fabrics, meshes, cloth or netting; wound repair devices like bone plates, orthopedic rods and screws, or catheters; and prosthetic devices such as

15 hip, knee, and dental implants. All of these devices provide a specific function in treatment of the body. However, the devices when used alone may cause certain problems.

For example, sutures and catheters in human or animal skin are usually bandaged to prevent infection by pathogenic organisms and to absorb escaping bodily fluids. The presence of infection causing organisms on implants, such as sutures and catheters, is a particularly serious concern since bacteria are likely

25 to become more active on foreign bodies. However, conventional bandages fail to adequately seal wounds or holes in the body where bodily fluids can escape and organisms can penetrate. Therefore, it is desireable to sufficiently seal such wounds thereby reducing the

30 chances of infection and loss of bodily fluid. When wounds in internal tissue are sealed, it is particularly important that the seal is capable of biodegrading or bioeroding so it will not have to be surgically removed.

Wound covering devices are normally draped over the treatment site and held in place by sutures or adhesives. However, the suturing of these coverings in place is often tedious and time-consuming and not desireable in many body sites. The adhesives are normally used external to the body and not applied

40 directly to the affected tissue but to adjacent healthy

tissue because they must be removed. It is desireable that a biocompatible material could be used to adhere wound coverings such as fabrics, meshes and bandages directly to the affected tissue and be biodegradable so 5 that it would not have to be removed as the tissue heals.

Certain implants such as screws or plates can have rough surfaces which cause abrasions on nearby tissue. Other implants such as clips and sutures can 10 cause discomfort and may interfere with the function of nearby tissue. Accordingly, it is desirable to place a smooth coating on the rough surfaces of implants in order to decrease discomfort and reduce damage to nearby tissue.

15 Implanting a medical device such as an artificial hip or joint usually requires a treatment regime of antibiotics administered topically, orally and/or intravenously in order to reduce infection. Current recommendations suggest intravenously 20 administering antibiotics for a period of 72 hours or less after implant surgery. See Total Joint Replacement, 1991, W.B. Saunders Company, Nelson, "Prevention of Postoperative Infections," pages 77-86. In addition, topical antibiotic irrigations are common 25 during the operative procedure. Even during relatively routine procedures, such as closing a wound with sutures or staples, a topical antibacterial ointment cream such as a mixture of vancomycin, polymyxin B, and neosporin is often applied to reduce infection. Since bacteria 30 are likely to become more active on foreign bodies, it is desirable to provide an effective antibiotic regime at the implant site rather than rely on periodic injections or administration of antibiotic. Accordingly, it is desirable to provide an implant which 35 releases a prescribed amount of antibiotic over a predetermined period of time.

Implants may cause pain and/or tend to be rejected by the body host. Accordingly, drugs and medicaments which prevent infection, relieve pain, promote healing and suppress rejection are typically administered to patients undergoing or having undergone implant surgery. Rather than subject a patient to a regime of intravenously or orally administered drugs, it is desirable to provide at the implant site a drug or medicament which is released over a predetermined period of time to relieve pain, promote healing, suppress rejection and the like.

Summary of the Invention

The present invention provides an adjunctive polymer system for coating a medical device which is a surgically implantable; a method for enhancing the compatibility of a surgically implantable device; a bandage coated with an adjunctive polymer system; a method for sealing a wound in body tissue; a medical device which is a surgically implanted device coated with a solid matrix; and a method for treating bone disorders.

The medical device is a combination of a first component which is a surgically implantable device (SID) and a second component which is an adjunctive polymer system (APS). The combination may be used in any form that will allow contact between the adjunctive polymer system and the body tissue into which the medical device is implanted. Generally, those forms include a coating or impregnation of the adjunctive polymer system upon the surgically implantable device prior to implantation; application of the adjunctive polymer system to the body tissue followed by implantation thereon of the surgically implantable device; and implantation of the surgically implantable device followed by coating thereon the adjunctive polymer system.

The first component of the medical device, namely the surgically implantable device, includes a mechanical implant used in a human or animal body. Generally, mechanical implants are used in combination with body tissue or organs temporarily, permanently, or semi-permanently, to remedy a problem and can be removed surgically or by biodegrading and/or bioeroding within the body. Exemplary implants include bandages, sutures, staples, clamps, fabric, meshes, webbing, cloth, netting, carbon fibers, artificial bones, screws, bone plates, orthopedic rods, nails, silicone valves, hip implants, knee implants, artificial hearts, replacement teeth, dental implants, catheters, and the like. Many of the above listed devices include devices, such as bandages, sutures, staples and the like, which can be applied topically and internally. For example, a bandage can be placed on exterior tissue, such as skin or mucous membrane, or on internal tissue, such as a liver. If desired, the surgically implantable device can contain a biologically active material which can be released therefrom. Suture fiber, cloth and the like can be capable of releasing drugs over time.

The second component of the medical device, namely the adjunctive polymer system, produces a solid matrix when it is contacted with water or a water-based environment which is normally found inside a human or animal body. Body tissue normally contains sufficient water or fluid to form the solid matrix. The adjunctive polymer system contains (a) a pharmaceutically acceptable, biodegradable thermoplastic polymer that is substantially insoluble in water or human or animal body fluids, and a biocompatible organic solvent which solubilizes the polymer and is miscible or dispersible in water or human or animal body fluids; or (b) a pharmaceutically acceptable, biodegradable *in situ* reactive prepolymer. For the thermoplastic polymer, upon contact with water or human or animal body fluids,

the organic solvent disperses and the thermoplastic polymer coagulates to form a solid matrix. The in-situ reactive prepolymer is mixed with a catalyst or initiator just prior to its introduction in the body where it polymerizes to form a solid implant.

The thermoplastic polymer component of the adjunctive polymer system can be any thermoplastic polymer or copolymer that is biocompatible, pharmaceutically acceptable and biodegradable by cellular action and/or by the action of body fluids. Preferably, the thermoplastic polymer is a polylactide, polyglycolide, polycaprolactone, or copolymer thereof. The organic solvent component of the adjunctive polymer system can be any solvent which solubilizes the thermoplastic polymer component and is biocompatible, pharmaceutically acceptable and soluble in water. Preferably, the organic solvent is N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethyl sulfoxide, propylene carbonate and ethyl lactate due, at least in part, to their solvating ability and their biocompatibility.

The in situ reactive prepolymer component of the adjunctive polymer system can be any prepolymer that is capable of cross-linking in situ to form a thermoset polymeric or copolymeric solid which is biocompatible, pharmaceutically acceptable and biodegradable by cellular action and/or by the action of body fluids. Preferably, the in situ reactive prepolymer is an acrylic ester-terminated biodegradable prepolymer. The in situ reactive prepolymer may include a biocompatible curing agent or catalyst, which is capable of enhancing the cross-linking reaction of prepolymers. A preferred curing agent for the acrylic ester-terminated biodegradable prepolymer is benzoyl peroxide. The composition can be a neat liquid or it can include a pharmaceutically acceptable organic solvent that is soluble in water and body fluids.

The adjunctive polymer system can contain additional components such as a biologically active material which can be released from the solid matrix at a desired rate and over a desired period of time, and an agent which controls the rate of release of the biologically active material. The biologically active material includes any biologically, physiologically, or pharmacologically active substance that acts locally or systemically in a human or animal body. Exemplary biological active materials include antibiotics, analgesics, growth promoting agents, clotting agents, anesthetics, antiseptics, antioxidants and the like. Preferably, the solid matrix releases an effective amount of biologically active agent at the implanted site to reduce infection, pain, etc. or to enhance healing, growth, etc. in local tissue. Rate modifying agents can be used to control the rate of release of the biologically active material.

The adjunctive polymer system can include a pore forming agent for forming pores in the solid matrix. Pore forming agents include organic solvents and water soluble materials which dissolve in human or animal body fluid. It may be desirable to create pores in the solid matrix to allow the solid matrix to be capable of passing fluid or allowing tissue ingrowth, or to control the rate of release of biologically active material from the solid matrix.

The combination of the implantable device and the adjunctive polymer system can be used as the implantable device is normally intended. The adjunctive polymer system enhances the compatibility of the surgically implantable device with body tissue. For example, the adjunctive polymer system is capable of providing a smooth surface on implants thereby reducing the occurrence of abrasions on nearby tissue caused by rough edges on implants. It can be applied to metallic screws, nails, bone plates, orthopedic rods, dental

implants, sutures, staples, clips, bandages and the like to cover rough surfaces and/or to hold them in place. When applied over suture or staple knots, the adjunctive polymer system additionally helps prevent the knots from 5 slipping.

In addition, the adjunctive polymer system can penetrate into holes/voids in tissue created by an implant and act as caulking to provide a tight seal around the implant which reduces loss of body fluids and 10 chances of infection. For example, the adjunctive polymer system can be applied around transcutaneous and percutaneous catheter sites where it seeps into the surgical incision, solidifies, adheres the catheter to the tissue and forms a tight seal to reduce chances of 15 bacteria infection. Similarly, the adjunctive polymer system can be applied around metallic screws, bone plates, orthopedic rods, dental implants and the like to fill voids, provide better adhesion or adaptation and/or retention, and to reduce chances of infection. It can 20 also be used for colostomy where there is an opening to the stomach or intestine that needs protection.

The adjunctive polymer system can be applied as a light or thin coating as well as a thick coating. The adjunctive polymer system can be applied to an 25 implantable medical device before or after it is implanted, and can be applied by brushing, spraying, dipping, extruding, injecting and the like, and by means including a syringe, needle, cannula, pump, and the like.

30 Wound dressings and repair devices including surgical fabric, mesh and the like can be used in combination with the adjunctive polymer system and applied to organs or tissue as a patch or covering. Such fibrous devices can be used, for example, for 35 vascular grafts and for healing wounds. The fabric or mesh provides strength and the adjunctive polymer system provides adhesion.

The fibrous device can be soaked in the adjunctive polymer system before it is applied to the tissue or organ. Alternatively, the adjunctive polymer system can be applied directly to the wound and, if
5 desired, allowed to partially coagulate, and the fibrous device can be applied thereon, or the fibrous device can be applied directly to the wound and the adjunctive polymer system can be applied over the fibrous device.
If desired, the adjunctive polymer system can penetrate
10 into the wound and help hold the tissue together while providing a seal which resists contamination during the healing process.

Upon contact with water or human or animal body fluid, the adjunctive polymer system coagulates or
15 cures into a solid matrix but remains in contact with the implantable device and the organ or tissue. The length of time between application of the adjunctive polymer system to body tissue and formation of the solid matrix is, for the thermoplastic polymer system, a
20 function of moisture level in or near the tissue, and the diffusion or dispersion rate of the solvent from the polymer. The rate can be accelerated by adding external water. For the thermoset polymer system, the cure time is a function of the reaction rate of the reactive
25 prepolymer, etc. Over time, the solid matrix biodegrades or bioerodes within the body and is metabolized and discharged without the need for further surgery. Many implantable devices, such as sutures and bandages, can similarly be designed to biodegrade or
30 bioerode within a body.

Bone disorders can be treated by placing the adjunctive polymer system containing a biologically active material directly into bone marrow via an osteostent or osteopore. For example, chronic anemia
35 can be treated by injecting the adjunctive polymer system containing erythropoietin (EPO) into an osteostent or osteopore where it contacts bone marrow.

As the adjunctive polymer system forms a solid matrix, the erythropoietin begins diffusing therefrom stimulating the marrow stem cells to produce more red blood cells.

5

Detailed Description of the Invention

As used herein, the phrase "human or animal" refers to any creature including a mammal, an animal, a bird, a reptile, etc.

- 10 The medical device according to the present invention is a combination of a first component which is a surgically implantable device and a second component which is an adjunctive polymer system. The combination can be used practically anywhere within the body of a
15 patient. Exemplary places for use include soft tissue such as muscle or fat; hard tissue such as bone; or a cavity or pocket such as the periodontal, oral, vaginal, rectal, nasal, or the cul-de-sac of the eye. Additional places in the body where the combination can be used
20 will be readily appreciated in view of the following teaching of the present invention.

The Surgically Implantable Device

- 25 The first component, namely the surgically implantable device, includes structural or prosthetic devices such as knee and hip implants, metal plates, screws, nails, stainless steel rods, bone replacement material, silicone valves or other silicone prothesis, artificial hearts, replacement teeth and jaw replacement
30 and the like; devices which hold tissue in place such as sutures, staples, cloth, netting, webbing and the like; and devices designed to permit injection and/or withdrawal of fluids or to keep a passage open such as catheters and the like.
35 The surgically implantable device can incorporate a biologically active material which can be released over time in a body. The type and amount of

biologically active material which can be incorporated into the surgically implantable device can be determined according to the teachings of this invention with respect to the adjunctive polymer system or according to 5 known products. For example, suture fiber can contain a biologically active material which can be released into tissue over time.

The various surgically implantable devices which can be used in combination with the adjunctive 10 polymer system will be readily appreciated in view of the following teaching of the present invention.

The Adjunctive Polymer System

The second component, namely the adjunctive 15 polymer system, contains (a) a pharmaceutically acceptable, biodegradable thermoplastic polymer that is substantially insoluble in water or human or animal body fluids, and a biocompatible organic solvent which solubilizes the polymer and is miscible or dispersible 20 in water or human or animal body fluids; or (b) a pharmaceutically acceptable, biodegradable *in situ* reactive prepolymer; or both in admixture. For the thermoplastic polymer, upon contact with water or human or animal bodily fluids, the organic solvent disperses 25 and the polymer coagulates to form a solid matrix. The *in situ* reactive prepolymer when combined with a curing agent just prior to insertion into the body polymerizes or crosslinks to form a solid matrix. The solid matrix is alternatively referred to herein as "the matrix" and 30 "the polymer matrix."

The adjunctive polymer system forms the solid matrix in the presence of water or human or animal body fluids as the organic solvent disperses from the adjunctive polymer system and the thermoplastic polymer 35 coagulates, or as the *in situ* reactive prepolymer cures to form a thermoset polymer. If desired, a biologically active material can be present in the adjunctive polymer

system and, subsequently, incorporated into the solid matrix where it is released over time. In addition, the adjunctive polymer system can contain an agent that helps control the rate of release of the biologically

- 5 active material and/or an agent which affects the pore sizes in the solid matrix. Thus, if a biologically active material is present in the solid matrix having pores, it diffuses through the fluid-filled pores at a controlled rate. The rate at which the biologically
- 10 active material departs the solid matrix can be a function of the rate at which the polymer biodegrades if the biologically active material cannot diffuse through the polymer matrix and if no pores are present or if the pores are too small.

- 15 The adjunctive polymer system and the solid matrix formed therefrom are pharmaceutically acceptable and biodegradable and/or bioerodable within the body of a human or animal. The biodegradation enables a patient to metabolize the polymer matrix so that it can be
- 20 discharged by the patient without the need for further surgery to remove it. Because the adjunctive polymer system and solid matrix are biocompatible, the insertion process and the presence of the adjunctive polymer system and, subsequently the solid matrix, within the
- 25 body do not cause substantial tissue irritation or necrosis at the implant site.

- 30 The present invention is particularly advantageous because of the adhesive properties of the biodegradable, biocompatible adjunctive polymer system which allows it to be used as an adhesive in combination with human or animal tissue. As the adjunctive polymer system forms the solid matrix in the presence of water or human or animal body fluid, it remains adhered to tissue it contacted in the liquid state but does not
- 35 adhere to other tissue it may contact after solidifying. The coating on the solid matrix can be smooth. This is important when using an implantable device and

adjunctive polymer system in a tight place where other surgical adhesives would cause problems by adhering to nearby organs or tissue.

The adjunctive polymer system can have a wide range of viscosities depending on the particular use for which it is designed. For example, the viscosity of the adjunctive polymer system can be as low as water or as high or higher than molasses. The viscosity can be altered by selection of the polymer or *in situ* reactive prepolymer or other component used therein and by the concentration of the polymer in the biocompatible solvent. It may be readily appreciated how polymer molecular weight and degree of crosslinking affect viscosity. Thus, the viscosity of the adjunctive polymer system can be designed for a particular application. The adjunctive polymer system can have a low viscosity when it is intended to form a thin film on an implanted medical device. This may be necessary when it is being used in a compact place such as a joint or when it is intended to seep into small holes in tissue created by sutures, staples, catheters and the like. Alternatively, the adjunctive polymer system can be more viscous when it is intended to be applied as a thicker coat to seal a wound or provide a barrier against the rough edges of a bone screw.

The following is a more detailed identification of ingredients which can make up the adjunctive polymer system useful in the present invention.

30

a) **Pharmaceutically Acceptable, Biodegradable Thermoplastic Polymer**

The pharmaceutically acceptable, biodegradable thermoplastic polymer which can be used in the adjunctive polymer system is insoluble in water or human or animal body fluids. Preferably, the thermoplastic polymer is substantially insoluble, more preferably essentially completely insoluble in water and body

fluids. Thus, in an aqueous media, the polymer coagulates and forms a solid matrix.

The thermoplastic polymer can be a homopolymer, copolymer, terpolymer, etc. Examples of 5 suitable thermoplastic polymers which can be used to form the solid matrix include polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, 10 polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid) polymers, 15 polymaleic anhydrides, poly(methylvinyl) ethers, poly(amino acids), chitin, chitosan, and copolymers, terpolymers, or combinations or mixtures of the above materials, and with other materials.

Preferred thermoplastic materials are the polylactides, polyglycolides, polycaprolactones, and 20 copolymers and terpolymers thereof. These polymers can be used to advantage in the adjunctive polymer system in part because they show excellent biocompatibility. They produce little, if any, tissue irritation, inflammation, necrosis, or toxicity. In the presence of water, these 25 polymers produce lactic, glycolic, and hydroxycaproic acid, respectively, which are readily metabolized by the body. The polylactides and polycaprolactones can also incorporate glycolide monomer to enhance the resulting polymer's degradation.

Depending on the desired softness and 30 flexibility of the resulting solid matrix, rate and extent of bioactive material release, rate of degradation, and the like, the amount and type of polymer can be varied to produce the desired result. 35 For example, for a relatively soft and flexible polymer system, copolymers with a low Tg can be used, primarily the lactide/caprolactone copolymers. The ratio of

glycolide to lactide to caprolactone can also be varied to effect water adsorption, which increases with an increasing amount of the more hydrophilic monomer. The hydrophilic character of these monomers increases in the 5 series as caprolactone < lactide < glycolide.

The solubility or miscibility of a thermoplastic polymer in the organic solvent of the adjunctive polymer system will vary according to factors such as crystallinity, hydrophilicity, capacity for 10 hydrogen bonding and molecular weight of the polymer. Consequently, the molecular weight and the concentration of the polymer in the solvent are adjusted to achieve desired miscibility, as well as a desired release rate for the incorporated bioactive material. Highly 15 preferred thermoplastic polymers are those having solubility parameters such as a low degree of crystallization, a low degree of hydrogen bonding, low solubility in water, and high solubility in organic solvents.

According to the practice of the invention, the adjunctive polymer system of pharmaceutically acceptable, biodegradable thermoplastic polymer and solvent is a stable liquid substance. If a bioactive 20 material is used, either a homogenous solution of the bioactive material in organic solvent, or a suspension 25 or dispersion of the bioactive material in the solvent results. In either case, the polymer is substantially soluble in the organic solvent. Upon placement into an aqueous medium, the solvent will dissipate and the 30 polymer will solidify to form the solid polymeric matrix containing, if desired, a bioactive material.

b) Biocompatible Organic Solvents

The biocompatible organic solvent which can be 35 used in the adjunctive polymer system is capable of solubilizing the thermoplastic polymer and is miscible or dispersible in water or human or animal body fluids.

Preferably, the solvent causes relatively little, if any tissue irritation or necrosis at the site of the injection and implantation. The solvent is water-soluble so that it will quickly disperse from the 5 polymeric composition into an aqueous medium such as body fluids. Concomitant with the dispersion of solvent the polymer coagulates into the solid matrix. As the polymer coagulates the solvent dispersion causes pore formation within the polymer composition. Generally, 10 the coagulated polymer will be microporous.

The degree of polarity of the solvent should be effective to provide at least about 10% solubility in water, and to dissolve, disperse or suspend the polymer component. The concentration of polymer in solution can 15 be adjusted such that the solvent will rapidly and effectively dissipate. This concentration can range from about 0.01g/ml to that of a saturated solution

Suitable solvents include those liquid organic compounds meeting the foregoing criteria. Examples 20 include, but are not limited to, N-methyl-2-pyrrolidone (NMP); 2-pyrrolidone (2-pyrol); C₂-C₆ alkanols; 2-ethoxyethanol; alkyl esters such as 2-ethoxyethyl acetate, ethyl acetate, ethyl lactate, ethyl butyrate, diethyl malonate, diethyl glutarate, tributyl citrate, 25 acetyl-tri-n-hexylcitrate, diethyl succinate, tributyrin, isopropyl myristate; carbonates such as propylene carbonate, dimethyl carbonate; ethylene glycol dimethyl ether; propylene glycol; 1,3-butylene glycol; ϵ -caprolactone; γ -butyrolactone; dimethylformamide; 30 dimethylacetamide; dimethyl sulfoxide; dimethyl sulfone; cyclic alkyl amides such as caprolactam; decylmethyl-sulfoxide; oleic acid; N,N-dimethyl-m-toluamide; solketal; and 1-dodecylazacycloheptan-2-one. The preferred solvents are N-methyl-2-pyrrolidone, 35 2-pyrrolidone, dimethyl sulfoxide, propylene carbonate and ethyl lactate due, at least in part, to their solvating ability and their biocompatibility.

The solvents for the adjunctive polymer system are chosen for compatibility and appropriate solubility of the polymer. Lower molecular weight thermoplastic polymers will normally dissolve more readily in the 5 solvents than high molecular weight polymers. As a result, the concentration of a thermoplastic polymer dissolved in the various solvents differs depending upon type of polymer and its molecular weight. Conversely, the higher molecular weight thermoplastic polymers will 10 tend to coagulate or solidify faster than the very low molecular weight thermoplastic polymers. Moreover, the higher molecular weight polymers tend to give higher solution viscosities than the low molecular weight materials. Thus, depending on the desired application 15 of the adjunctive polymer system, the molecular weight and the concentration of the polymer in the solvent are controlled.

A solvent mixture can be used to increase the coagulation rate of thermoplastic polymers that exhibit 20 a slow coagulation rate. In such a system one component of the mixture is typically a good solvent for the thermoplastic polymer, and the other component is a poorer solvent or a nonsolvent. The two liquids are mixed at a ratio such that the thermoplastic polymer is 25 still soluble, but precipitates with the slightest increase in the amount of nonsolvent, such as water in a physiological environment. By necessity, the solvent system must be miscible with both the thermoplastic polymer and water. An example of such a binary solvent 30 system is the use of NMP and ethanol for low molecular weight DL-PLA. The addition of ethanol to the NMP/polymer solution increases its coagulation rate significantly.

When the thermoplastic liquid composition is 35 added to the aqueous medium, the organic solvent diffuses into the surrounding medium (body fluids or an external water medium) and the polymer coagulates to

form the s lid matrix having pores, preferably micropores. The more or less simultaneous diffusion and coagulation produce a matrix with a core and skin structure that in part is believed to be a factor in the establishment of the desired control of rate and extent of release of biologically active material, if present.

5
c) **Pharmaceutically Acceptable, Biodegradable In Situ Reactive Prepolymer**

10 The pharmaceutically acceptable, biodegradable in situ reactive prepolymer which can be used in the adjunctive polymer system can cure in the presence of water or body fluids to form a thermoset polymer. If desired, a curing agent such as a curing catalyst can be 15 used to cure the reactive prepolymer. The resulting thermoset polymer is pharmaceutically acceptable, biodegradable and insoluble in water or human or animal body fluids.

20 The reactive prepolymers can be liquid and/or combined with a biocompatible organic solvent as described above to provide a liquid. Any of the biodegradable polymers previously described for the thermoplastic system and having or being adapted to have cross-linkable or curable functional groups can be used. 25 Prepolymers can be used. However, low molecular weight oligomers are preferred. These are usually liquids at room temperature. They are also preferably functionalized with end groups that are reactive with acryloyl chloride to produce acrylic ester capped 30 prepolymers. Acrylic prepolymers for use in the liquid composition may be synthesized according to a variety of methods including, but not limited to, reaction of a carboxylic acid, such as acrylic or methacrylic acid, with an alcohol; reaction of a carboxylic acid ester, 35 such as methyl acrylate or methyl methacrylate, with an alcohol by transesterification; reaction of a carboxylic acid chloride such as acryloyl chloride with an alcohol, and reaction of an isocyanatoalkyl acrylate, such as

isocyanat ethyl methacrylate, with an alcohol. These methods are known in the art.

A preferred biodegradable polymer system is produced from poly(DL-lactide-caprolactone), or 5 "DL-PLC." Low molecular weight polymers or oligomers produced from these materials are flowable liquids at room temperature. To prepare the DL-PLC polymer matrix, hydroxy-terminated PLC prepolymers are initially synthesized via copolymerization of DL-lactide or L- 10 lactide and ϵ -caprolactone with a multifunctional polyoyl initiator and a catalyst. Catalysts useful for the preparation of these prepolymers are preferably basic or neutral ester-interchange (transesterification catalysts). These include, for example, metallic esters 15 of carboxylic acids containing up to 18 carbon atoms, such as formic, acetic, lauric, stearic, and benzoic acids. Stannous octoate and stannous chloride are preferred catalysts.

In the above reaction, if a bifunctional 20 polyester is desired, a bifunctional polyol chain initiator such as ethylene glycol is employed. If a trifunctional polyester is desired, a trifunctional polyol chain initiator such as trimethylolpropane is employed. The amount of chain initiator used determines 25 the resultant molecular weight of the polymer or copolymer. For example, a high concentration of a bifunctional chain initiator provides an initiator molecule for each polymer chain, whereas a low concentration of bifunctional initiator provides one initiator molecule for every two polymer chains.

The diol or polyol-terminated prepolymers are converted to acrylic-ester prepolymers by any suitable method, as for example, by acylation of the alcohol terminal end with acryloyl chloride by means of a 35 Schotten-Baumann technique.

A curing agent, such as a catalyst, may be added to the acrylic prepolymer mixture to enhance

cr ss-linking of the prepolymers and the subsequent solidification of the resulting polymer to form a matrix. For example, a peroxide such as benzoyl peroxide may be added to the acrylic prepolymer mentioned above. Optionally, other acrylic monomers may be added to the acrylic prepolymer mixture before adding the curing agent.

This thermoset polymer forming system can be used wherever a bioactive material can be advantageously released from a biodegradable implant. Because the reactive prepolymer remains a liquid for a short time after addition of the curing agent, the liquid prepolymer/bioactive material/curing agent mixture preferably is immediately thereafter inserted into the aqueous medium. The curing steps can be accomplished using known means, e.g., by exposure to radiation, with or without a curing agent.

The thermoset liquid composition can contain one or more materials to form a microporous matrix. These include water-soluble materials such as sugars, salts, and polymers, or solvents. If a solvent is used, the solvent may be present in an amount suitable to form a porous matrix, but not so high as to substantially dilute the prepolymers such that the resultant polymer would be only lightly cross-linked.

d) Biologically Active Materials

The terms "drug," "medicament," or "bioactive material" (i.e., biologically active material) as used herein include, biologically, physiologically, or pharmacologically active substances that act locally or systemically in the human or animal body.

When a biologically active agent is to be released by the solid matrix, the agent is dissolved in the adjunctive polymer system to form a homogenous solution or dispersed in the adjunctive polymer system to form a suspension. Various forms of the medicaments

r biologically active materials can be used which are capable of being released from the solid matrix into adjacent tissues or fluids. The medicaments are at least very slightly water soluble, preferably moderately 5 water soluble, and are diffusible through the polymeric composition. They can be acidic, basic, or amphoteric salts. They can be nonionic molecules, polar molecules, or molecular complexes capable of hydrogen bonding. They can be in the form of ethers, esters, amides and 10 the like, or polymer drug conjugates and the like, which are biologically activated when introduced into the human or animal body.

Generally, any drugs or bioactive materials that can be dissolved or dispersed in an aqueous 15 environment can be utilized in the adjunctive polymer system. Representative drugs or bioactive materials that can be used in the adjunctive polymer system or solid matrix of the present invention include, but are not limited to, peptide drugs, protein drugs, 20 desensitizing materials, antigens, anti-infective agents such as antibiotics, antimicrobial agents, antiviral, antibacterial, antiparasitic, antifungal substances and combination thereof, antiallergenics, androgenic steroids, decongestants, hypnotics, steroidal anti- 25 inflammatory agents, anti-cholinergics, sympathomimetics, sedatives, miotics, psychic energizers, tranquilizers, vaccines, estrogens, progestational agents, humoral agents, prostaglandins, analgesics, antispasmodics, antimalarials, 30 antihistamines, cardioactive agents, nonsteroidal anti-inflammatory agents, antiparkinsonian agents, antihypertensive agents, β -adrenergic blocking agents, nutritional agents, and the benzophenanthridine alkaloids. The agent may further be a substance capable 35 of acting as a stimulant, sedative, hypnotic, analgesic, anticonvulsant, and the like.

The adjunctive polymer system can contain a large number of biologically active agents either singly or in combination. The biologically active agents can be in a controlled release component which is dissolved, dispersed or entrained in the adjunctive polymer system. The controlled release component can include microstructures, macrostructures, conjugates, complexers, low water-solubility salts and the like. Microstructures include nanoparticles, cyclodextrins, 10 microcapsules, micelles, liposomes and the like. Macrostructures include fibers, beads and the like. Controlled release compositions are disclosed in copending U.S. Patent application Serial No. _____, filed April 6, 1994, entitled "Liquid 15 Delivery Compositions," the disclosure of which is incorporated herein by reference.

It is preferred that the biologically-active agents contained and released from the adjunctive polymer system are those that supplement and/or improve 20 the benefits of the medical device with which the adjunctive polymer system is combined. Examples of these biologically-active agents include, but are not limited to:

Anti-inflammatory agents such as 25 hydrocortisone, prednisone, fludrotisone, triamcinolone, dexamethasone, betamethasone, and the like.

Anti-bacterial agents such as penicillins, cephalosporins, vancomycin, bacitracin, polymycins, tetracyclines, chloramphenicol, erythromycin, 30 streptomycin, quinolone, and the like.

Antifungal agents such as nystatin, gentamicin, miconazole, tolnaftate, undecyclic acid and its salts, and the like.

Analgesic agents such as salicylic acid, 35 salicylate esters and salts, acetaminophen, ibuprofen, morphine, phenylbutazone, indomethacin, sulindac, tolmetin, zomepirac, and the like.

Local anesthetics such as cocaine, benzocaine, novocaine, lidocaine, and the like.

The bioactive material may also be a substance, or metabolic precursor thereof, which is capable of promoting growth and survival of cells and tissues, or augmenting the activity of functioning cells, as for example, blood cells, neurons, muscle, bone marrow, bone cells and tissues, and the like. For example, the bioactive material may be a nerve growth promoting substance, as for example, a ganglioside, phosphatidylserine, a nerve growth factor, brain-derived neurotrophic factor. The bioactive material may also be a growth factor for soft or fibrous connective tissue as, for example, a fibroblast growth factor, an epidermal growth factor, an endothelial cell growth factor, a platelet derived growth factor, an insulin-like growth factor, a periodontal ligament cell growth factor, cementum attachment extracts, and fibronectrin.

To promote bone growth, the biologically active material may be an osteoinductive or osteoconductive substance. Suitable bone growth promoting agents include, for example, osteoinductive factor (OIF), bone morphogenetic protein (BMP) or protein derived therefrom, demineralized bone matrix, and releasing factors thereof. Further, the agent may be a bone growth promoting substance such as hydroxyapatite, tricalcium phosphate, a di- or polyphosphonic acid, an anti-estrogen, a sodium fluoride preparation, a substance having a phosphate to calcium ratio similar to natural bone, and the like. A bone growth promoting substance may be in the form, as for example, of bone chips, bone crystals or mineral fractions of bone and/or teeth, a synthetic hydroxyapatite, or other suitable form. The agent may further be capable of treating metabolic bone disorders such as abnormal calcium and phosphate metabolism by, for example, inhibiting bone resorption, promoting bone

mineralization, or inhibiting calcification. The active agent may also be used to promote the growth and survival of blood cells, as for example, a colony stimulating factor, and erythropoietin.

5 The biologically-active agent may be included in the compositions in the form of, for example, an uncharged molecule, a molecular complex, a salt, an ether, an ester, an amide, polymer drug conjugate, or other form to provide the effective biological or
10 physiological activity.

The bioactive material can be miscible in the polymer and/or solvent to provide a homogenous mixture with the polymer, or insoluble in the polymer and/or solvent to form a suspension or dispersion with the
15 polymer. It is highly preferred that the biologically active material be combined with the thermoset polymer forming composition almost immediately prior to administration of the composition to the implant site. It is further preferred that the bioactive material does
20 not contain functional groups that could interfere with the cross-linking reaction of the thermosetting polymer. These conditions are readily determined by those of skill in the art simply by comparing the structure of the bioactive material and the reacting moieties of the
25 thermosetting polymer.

Upon formation of the solid matrix from the adjunctive polymer system, the biologically active material becomes incorporated into the polymer matrix. The bioactive material will be released from the matrix
30 into the adjacent tissues or fluids by diffusion and polymer degradation mechanisms. Manipulation of these mechanisms also can influence the release of the bioactive material into the surroundings at a controlled rate. For example, the polymer matrix can be formulated
35 to degrade after an effective and/or substantial amount of the bioactive material is released from the matrix. Release of a material having a low solubility in water,

as for example a peptide or protein, typically requires the degradation of a substantial part of the polymer matrix to expose the material directly to the surrounding tissue fluids. Thus, the release of the 5 biologically active material from the matrix can be varied by, for example, the solubility of the bioactive material in water, the distribution of the bioactive material within the matrix, or the size, shape, porosity, solubility and biodegradability of the polymer 10 matrix, among other factors. The release of the biologically active material can facilitate pore formation. The release of the biologically active material from the matrix is controlled relative to its intrinsic rate by varying the polymer composition, 15 molecular weight, and/or polymer concentration, and by adding a rate modifying agent to provide a desired duration and rate of release, as described above.

The polymer system is formulated to contain the bioactive material in an amount effective to provide 20 a desired biological, physiological and/or therapeutic effect. The "effective amount" of a biologically active material incorporated into the polymeric composition of the invention depends on a variety of factors, such as the desired release profile, the concentration of 25 bioactive material required for a desired biological effect, and the period of time over which the bioactive material needs to be released for desired treatment. Ultimately, this amount is determined by the patient's physician who will apply his experience and wisdom in 30 prescribing the appropriate kind and amount of bioactive material to provide therapy for the patient. There is generally no critical upper limit on the amount of bioactive material incorporated into the polymer solution. The only limitation is a physical limitation 35 for advantageous application, i.e., the bioactive material should not be present in such a high concentration that the solution or dispersion viscosity

is too high for use. The lower limit of bioactive material incorporated into the polymer system typically depends only on the activity of the bioactive material and the period of time desired for treatment.

5

e) Pore Forming Agent

Other additives can be used to advantage in further controlling the pore size in the solid matrix, which influences the structure of the matrix and the 10 release rate of a bioactive material or the diffusion rate of body fluids. For example, if the thermoplastic polymer liquid composition is too impervious to water or tissue ingrowth, a pore-forming agent can be added to generate additional pores in the matrix. Any 15 biocompatible water-soluble material can be used as the pore-forming agent. These agents can be either soluble in the adjunctive polymer system or simply dispersed within it. They are capable of dissolving, diffusing or dispersing out of both the coagulating and/or reacting 20 polymer matrix whereupon pores and microporous channels are generated. The amount of pore-forming agent (and size of dispersed particles of such pore-forming agent, if appropriate) within the adjunctive polymer system will directly affect the size and number of the pores in 25 the polymer matrix.

Pore-forming agents include any pharmaceutically acceptable organic or inorganic substance that is substantially miscible in water and body fluids and will dissipate from the forming and 30 formed matrix into aqueous medium or body fluids or water-immiscible substances that rapidly degrade to water soluble substances. The pore-forming agent may be soluble or insoluble in the thermoset polymer liquid composition of the invention. It is further preferred 35 that the pore-forming agent is miscible or dispersible in the organic solvent to form a uniform mixture. Suitable pore-forming agents include, for example,

sugars such as sucrose and dextrose, salts such as sodium chloride and sodium carbonate, and polymers such as hydroxylpropylcellulose, carboxymethylcellulose, polyethylene glycol, and polyvinylpyrrolidone. The size and extent of the pores can be varied over a wide range by changing the molecular weight and percentage of pore-forming agent incorporated into the polymer system.

Combination of Surgically Implantable Device and Adjunctive Polymer System

The adjunctive polymer system can be applied by any convenient technique. For example, the adjunctive polymer system can be applied by brushing, spraying, extruding, dipping, injecting and the like, and by means including a syringe, needle, cannula, pump, catheter and the like. The adjunctive polymer system can be applied in the form of a film, caulk, etc. However, to increase adhesion to body tissue, it may be desirable to remove excess water or body fluid from the surface of the tissue. Although the body tissue can and should be moist, it should not have a layer of fluid thereon if it is intended that the adjunctive polymer system adhere thereto. Alternatively, if it is undesirable for the adjunctive polymer system to adhere to body tissue when it is functioning, for example as caulk, it may be desirable to add additional water to the tissue surface.

The adjunctive polymer system can be applied to the implantable device at any time before, during, or after implantation. For example, it may be desirable to apply the adjunctive polymer to a catheter, package the coated catheter in a shrink-wrap film, and store the packaged catheter until it is used. Similarly, a bandage can be packaged in combination with the adjunctive polymer system for future use. Alternatively, it may be desirable to apply the adjunctive polymer system over an implant, such as a

bone screw or a suture line, or to tissue before implant surgery.

In the presence of sufficient water or body fluid, the adjunctive polymer system coagulates into a solid matrix. If desired, the amount of water in contact with the adjunctive polymer system can be controlled so as to control the rate of solid matrix formation.

In one embodiment of the present invention, 10 the combination of the adjunctive polymer system and the implantable device holds tissue in place. Conventional implantable devices used to hold tissue together can be used in the present invention. Such devices include sutures, ligatures, staples, clips, bandages, webbing 15 and the like. However, by coating the adjunctive polymer system on such devices, one can, as desired, advantageously increase the adhesion and/or adaptation of the device to the tissue, seal the wound to reduce loss of body fluid and chances of infection, provide a 20 smooth surface over the device, and administer drugs or medicaments directly at the desired site. As discussed above, biologically active agents can be added to the adjunctive polymer system to reduce infection, promote healing, relieve pain, etc.

Generally, the adjunctive polymer system can 25 be applied to sutures, staples and the like by brushing and spraying. However, the adjunctive polymer system can be applied by dipping or drawing the suture filament through the adjunctive polymer system before it is used 30 to hold tissue together. Advantageously, the adjunctive polymer system seeps or penetrate into the holes created by the sutures or staples, and seals the holes thereby preventing fluids such as blood, urine, bowel material and the like from leaking out through the suture holes 35 and bacteria or other contaminant from entering the wound. Alternatively, the adjunctive polymer system can be applied to an area before or during suturing to help

provide adhesion and/or to quickly administer a biologically active agent thereto.

When applied to incised or torn tissue, the adjunctive polymer system can help adhere the tissue and
5 to seal the wound to prevent body fluid from leaking out and to prevent germs or other debris from contaminating the wound. As the adjunctive polymer system penetrates into the wound, it mixes with water or body fluids and coagulates, or cures, into a solid matrix. Generally,
10 in internal tissues and organs such as arteries and veins, liver, pancreas, etc., there is usually sufficient body fluid within the tissue or organ to completely form the solid matrix. However, in some situations, there may not be enough body fluid present
15 to quickly and completely form the solid matrix. For example, when the adjunctive polymer system covers exposed sutures holding the outer layer of skin together, it may be helpful to add water to the adjunctive polymer system to increase the rate of
20 formation of the solid matrix.

Applying the biodegradable adjunctive polymer system as a film over exposed sutures to prevent penetration of bacteria from outside the body is particularly important in exterior wounds, dental
25 surgery, throat surgery, and the like, since the sutures would otherwise be exposed to the atmosphere.

In addition, the adjunctive polymer system can be used to improve knot retention in sutures and staples, and to ensure that clips and clamps remain
30 secure for a desired length of time. Since suture knots tend to loosen, it is desirable to apply a biodegradable composition thereto which adheres to the knot allowing it to hold more firmly.

Similarly, the adjunctive polymer system can
35 be used with catheters such as transcutaneous and percutaneous catheters. The adjunctive polymer system can be applied around the catheter site where it seeps

into the surgical incision, solidifies, adheres the catheter to the tissue and forms a tight seal to prevent bacterial infection. As discussed above, a catheter can be coated with the adjunctive polymer system and stored until it is used, or the adjunctive polymer can be applied to the wound site as caulk. Alternatively, the adjunctive polymer system can be applied to body tissue before the catheter is implanted. Thus, as the catheter is inserted the solid matrix forms around the wound site. Similarly, the adjunctive polymer system can be used for colostomy where there is an opening to the stomach or intestines that needs protection.

The adjunctive polymer system can be applied to other medical devices such as metallic screws, bone plates, orthopedic rods, dental implants and the like to enhance adaptation to body tissue. The adjunctive polymer system can help the device adhere to tissue and can be applied over rough surfaces to prevent abrasion to other tissue. The adjunctive polymer system can act as a caulking material to fill voids created between the device and body tissue and to provide a desired administration rate of biologically active agent at the desired site.

When used near or in conjunction with bone tissue, the adjunctive polymer system preferably contains a biologically active agent to prevent infection and aid in healing. For example, growth factors can advantageously be used with sintered metal or hydroxyapatite coatings that are porous in that the controlled release of the factor would provide better bone ingrowth. The same holds for other devices in which soft tissue ingrowth is needed such as muscle or ligament repair.

The adjunctive polymer system can be used for treating bone disorders. For example the adjunctive polymer system can contain erythropoietin (EPO) and can be placed in living bone marrow to treat patients

30

suffering from chronic anemia. Generally, the adjunctive polymer system is injected into the living bone marrow through an osteostent or osteopore. The EPO stimulates erythropoiesis.

5 The invention will be further described with reference to the following specific examples which are not intended to limit the scope of invention.

Example 1 (The Adjunctive Polymer System)

10 Adjunctive polymer systems A-G can be prepared by mixing the ingredients described below in a polyethylene container at room temperature.

System A: 50:50 Poly(DL-lactide-co-caprolactone) (20g)

15 N-methyl-2-pyrrolidone (80g)

System B: 75:25 Poly (DL-lactide-co-glycolide) (40g)

N-methyl-2-pyrrolidone (60g)

20 System C: Poly (DL-lactide) (40g)

N-methyl-2-pyrrolidone (60g)

System D: 50:50 Poly (DL-lactide-co-caprolactone) (15g)

N-methyl-2-pyrrolidone (80g)

25 Vancomycin (5g)

System E: 50:50 Poly (DL-lactide-co-glycolide) (40g)

N-methyl-2-pyrrolidone (50g)

Demineralized bone matrix (10g)

30

System F: Acrylic terminated copolymer of 15:85 poly

(DL-lactide-co- caprolactone (9.9g)

Benzoyl peroxide (0.1g)

35 System G: 50:50 Poly(DL-lactide-co-glycolide (50g)

N-methyl-2-pyrrolidone (50g)

Erythropoietin (10g)

Example 1

A dog's leg can be shaved and prepared for introduction of a transcutaneous catheter. The catheter can be inserted and System A sprayed on the wound site 5 to form a film which will solidify into a matrix in about 20 seconds.

The solid matrix will tightly adhere to the skin tissue and the catheter.

10 Example 2

A pig can be anesthetized, and a half inch incision made in the liver. The incision can be sutured and System B brushed over the suture line to form a film which will solidify into a solid matrix in about 2 15 minutes. The film will adhere to the liver tissue and the sutures, and seal the wound.

Example 3

A dog can be anesthetized, and a segment of 20 bone removed from the tibia of one leg. A stainless steel plate can be attached to the two sections of the tibia with bone screws. System C can then be brushed over the bone plate and screws to completely coat them. The liquid polymer will solidify into a solid matrix in 25 about 2 minutes and will adhere tightly to the plates and screws to provide a smooth surface.

Example 4

A rabbit can be anesthetized and a small 30 section of the back shaved. A half inch incision can be made in the back and sutured together with silk sutures. System D can be sprayed over the wound and suture site using an aerosol system. The liquid polymer will penetrate into the wound and around the sutures to form 35 a 20 μm film and solidify in about 20 seconds.

Example 5

A dog can be anesthetized and a small drill hole made in the molar section of the mandible. System E can then be applied to the surface of the drill hole 5 using a small syringe. The base section of the dental implant can be immediately screwed into the drill hole where the liquid polymer completely coats the interface between the implant and the bone tissue and solidify to form a tight seal and matrix for delivery of the 10 demineralized bone matrix.

Example 6

A dog can be anesthetized and a section of a vein removed. A vascular graft made with a Dacron 15 polyester mesh can be soaked in System F and sutured in place where the liquid prepolymer cures in 10 minutes to form a nonpervious graft coated with a biodegradable polymer.

Example 7

A rabbit can be anesthetized and a small drill hole made in the tibia such that it penetrates to the marrow. An osteostent can be screwed into the drill hole and the tissue sutured in place. System G can then 25 be injected into the osteostent device through the injection port. The liquid polymer will solidify with the osteostent in about 2 minutes where the drug will slowly release into the marrow space.

WHAT IS CLAIMED IS:

1. A medical device comprising a surgically implantable device for use with human or animal tissue and an adjunctive polymer system, said adjunctive polymer system comprising:
 - (a) a pharmaceutically acceptable, biodegradable thermoplastic polymer that is substantially insoluble in water or human or animal body fluids, and a biocompatible organic solvent which solubilizes said polymer and is miscible or dispersible in water or human or animal body fluids; or
 - (b) a pharmaceutically acceptable, biodegradable in situ reactive prepolymer.
2. The medical device according to claim 1, wherein said surgically implantable device is selected from the group consisting of sutures, staples, clamps, fabric, meshes, cloth, netting, webbing, carbon fibers, artificial bones, screws, bone plates, orthopedic rods, osteostents, nails, silicone valves, hip implants, knee implants, artificial hearts, replacement teeth, dental implants, and catheters.
3. The medical device according to claim 1, wherein said polymer is thermoplastic and is selected from the group consisting of polylactides, polyglycolides, polycaprolactones, polyanhydrides, polyamides, polyurethanes, polyesteramides, polyorthoesters, polydioxanones, polyacetals, polyketals, polycarbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(amino acids), poly(methyl vinyl ether), chitin, chitosan, and copolymers, terpolymers, and any combination thereof.

4. The medical device according to claim 3, wherein said thermoplastic polymer is selected from the group consisting of polylactide, polyglycolide, polycaprolactone and copolymers and terpolymers thereof.

5. The medical device according to claim 1, further containing a biocompatible curing agent capable of enhancing a cross-linking reaction of said pharmaceutically acceptable, biodegradable *in situ* reactive prepolymer.

6. The medical device according to claim 1, wherein said *in situ* reactive prepolymer is an acrylic ester-terminated biodegradable prepolymer.

7. The medical device according to claim 6, further comprising benzoyl peroxide as a biocompatible curing agent.

8. The medical device according to claim 1, further comprising a pharmaceutically acceptable organic solvent that is miscible or dispersible with water and body fluids in combination with said pharmaceutically acceptable, biodegradable *in situ* reactive prepolymer.

9. The medical device according to claim 1, wherein said biocompatible organic solvent is selected from the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, C₂-C₆ alkanols, 2-ethoxyethanol, alkyl esters, carbonates, ethylene glycol dimethyl ether, propylene glycol, 1,3-butylene glycol, ϵ -caprolactone, γ -butyrolactone, dimethylformamide, dimethylacetamide, dimethyl sulfoxide, dimethyl sulfone, cyclic alkyl amides, decylmethylsulfoxide, oleic acid, N,N-dimethyl-m-toluamide, solketal, 1-dodecylazacycloheptan-2-one, and any combination thereof.

10. The medical device according to claim 9, wherein said biocompatible organic solvent is selected from the group consisting of N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethyl sulfoxide, propylene carbonate, ethyl lactate, and any combination thereof.

11. The medical device according to claim 1, wherein said adjunctive polymer system additionally contains a biologically active material.

12. The medical device according to claim 11, wherein said biologically active material is selected from the group consisting of antibiotics, analgesics, growth promoting agents, clotting agents, anesthetics, antiseptics, antioxidants and mixtures thereof.

13. The medical device according to claim 1, wherein said surgically implantable device incorporates therein a biologically active material capable of being released therefrom when implanted in living tissue.

14. The medical device according to claim 1, wherein said adjunctive polymer system is capable of coagulating or curing in the presence of water or human or animal body fluids.

15. A method for enhancing the compatibility of a surgically implantable device in a body comprising steps of:

(a) applying an adjunctive polymer system to a surgically implantable device and body tissue, wherein said adjunctive polymer system comprises:

(i) a pharmaceutically acceptable, biodegradable thermoplastic polymer that is substantially insoluble in water or human or animal body fluids, and a biocompatible organic solvent which

- s lubricates said polymer and is miscible or dispersible in water or human or animal body fluids; or
- (ii) a pharmaceutically acceptable, biodegradable *in situ* reactive prepolymer;
- (b) implanting said surgically implantable device in body tissue.
16. The method according to claim 15, further comprising allowing said adjunctive polymer system to coagulate or cure in the presence of water or human or animal body fluid.
17. The method according to claim 15, wherein said adjunctive polymer system is applied to said surgically implantable device before said surgically implantable device is implanted.
18. The method according to claim 15, wherein said adjunctive polymer system is applied to said tissue before said surgically implantable device is implanted.
19. The method according to claim 15, wherein said surgically implantable medical device is selected from the group consisting of sutures, staples, clamps, fabric, meshes, cloth, netting, webbing, carbon fibers, artificial bones, screws, bone plates, orthopedic rods, osteostents, nails, silicone valves, hip implants, knee implants, artificial hearts, replacement teeth, dental implants, catheters and polymer beads.
20. The method according to claim 15, wherein said adjunctive polymer system is applied around a catheter.
21. The method according to claim 15, wherein said medical device is selected from the group consisting of

sutures, staples, clips, clamps, fabric, meshes, cloth, netting and webbing.

22. A bandage coated with an adjunctive polymer system or derivative thereof, wherein said adjunctive polymer system comprises:

- (a) a pharmaceutically acceptable, biodegradable thermoplastic polymer that is substantially insoluble in water or human or animal body fluids, and a biocompatible organic solvent which solubilizes said polymer and is miscible or dispersible in water or human or animal body fluids; or
- (b) a pharmaceutically acceptable, biodegradable *in situ* reactive prepolymer.

23. The bandage according to claim 22, wherein said bandage is biodegradable and selected from the group consisting of fabric, mesh, webbing, cloth, net, and combinations thereof.

24. The bandage according to claim 22, wherein a biologically active material is incorporated into said bandage, said adjunctive polymer system or both.

25. A method for sealing a wound in body tissue comprising steps of:

(a) applying an adjunctive polymer system to a bandage material and body tissue, wherein said adjunctive polymer system comprises:

- (i) a pharmaceutically acceptable, biodegradable thermoplastic polymer that is substantially insoluble in water or human or animal body fluids, and a biocompatible organic solvent which solubilizes said polymer and is miscible

- or dispersible in water or human or animal body fluids; or
- (ii) a pharmaceutically acceptable, biodegradable *in situ* reactive prepolymer;
- (b) allowing said adjunctive polymer system to coagulate or cure in the presence of body tissue.
26. A medical device comprising a surgically implanted device and a solid matrix, said solid matrix prepared from an adjunctive polymer system by:
- (a) adding water or human or animal body fluids to a pharmaceutically acceptable, biodegradable thermoplastic polymer that is substantially insoluble in water or human or animal body fluids, and a biocompatible organic solvent which solubilizes said polymer and is miscible or dispersible in water or human or animal body fluids; or
- (b) adding a catalyst or initiator to a pharmaceutically acceptable, biodegradable *in situ* reactive prepolymer prior to implantation.
27. The medical device according to claim 26, wherein the solid matrix is microporous.
28. The medical device according to claim 27, wherein said solid microporous matrix releases a biologically active material.
29. The medical device according to claim 26, wherein the implanted device is selected from the group consisting of sutures, staples, clamps, fabric, meshes, cloth, netting, webbing, carbon fibers, artificial bones, screws, bone plates, orthopedic rods, nails, silicone valves, hip implants, knee implants, artificial hearts, replacement teeth, dental implants, and catheters.

30. A method for treating bone disorders comprising:

(a) placing an adjunctive polymer system in an osteostent in living bone marrow, wherein said adjunctive polymer system comprises a pharmaceutically effective amount of a biologically active agent and:

- (i) a pharmaceutically acceptable, biodegradable thermoplastic polymer that is substantially insoluble in water or human or animal body fluids, and a biocompatible organic solvent which solubilizes said polymer and is miscible or dispersible in water or human or animal body fluids; or
- (ii) a pharmaceutically acceptable, biodegradable *in situ* reactive prepolymer; and

(b) allowing said adjunctive polymer system to coagulate or cure.

31. The method for treating bone disorders according to claim 30, wherein said adjunctive polymer system is injected into said osteostent or osteopore in living bone marrow.

32. The method for treating bone disorders according to claim 30, wherein said pharmaceutically effective amount of a biologically active agent is a sufficient amount of erythropoietin for stimulating erythropoiesis in patients suffering from chronic anemia.

PCT

WORLD INTELLECT.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: A61L 15/22, 17/00, 25/00, 27/00, A61L 29/00, 31/00, 15/42, 15/44		AJ	(11) International Publication Number: WO 95/28124 (13) International Publication Date: 26 October 1995 (26.10.95)
(21) International Application Number: PCT/US95/03259 (22) International Filing Date: 15 March 1995 (15.03.95) (30) Priority Data: 08/226,006 8 April 1994 (08.04.94) US		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARFO patent (KE, MW, SD, SZ, UC).	
(71) Applicant: ATRIX LABORATORIES, INC. (US/US); 2579 Midpoint Drive, Fort Collins, CO 80523 (US). (72) Inventors: DUNN, Richard, L.; 5021 Kitchell Way, Fort Collins, CO 80524 (US). YEWEY, Gerald, L.; Apartment 606, 451 Boardwalk Drive, Fort Collins, CO 80525 (US). SOUTHLAND, Jeffrey, L.; 2042 Carter Drive, Fort Collins, CO 80525 (US). URHEIM, John, E.; 3417 Taylor Lane, Fort Collins, CO 80523 (US). (74) Agent: BRUESS, Steven, C.; Merchant, Gould, Smith, Edell, Weiler & Schmidt, 3100 Norwest Center, 90 South 7th Street, Minneapolis, MN 55402 (US).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments. (80) Date of publication of the international search report: 15 February 1996 (15.02.96)	
(54) Title: AN ADJUNCTIVE POLYMER SYSTEM FOR USE WITH MEDICAL DEVICE (57) Abstract A medical device which is a surgically implantable device coated with an adjunctive polymer system. The adjunctive polymer system forms a solid matrix when introduced into a human or animal body. The adjunctive polymer system can contain a drug or a medicament which is released over time from the solid matrix. The adjunctive polymer system contacts body tissue into which the surgically implantable device is implanted.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	IS	Iceland
AU	Australia	GE	Georgia	NL	Netherlands
BE	Belgium	GK	Greece	NO	Niger
BG	Bulgaria	GR	Spain	NZ	Norway
BH	Bahrain	HU	Hungary	PL	New Zealand
BR	Brunei Darussalam	ID	Indonesia	PT	Portugal
CA	Canada	IE	Ireland	RO	Romania
CH	Switzerland	IL	Italy	RU	Russia
CN	China	IR	Iran	SE	Singapore
CO	Colombia	IS	Kyrgyzstan	SI	Slovenia
CR	Costa Rica	JO	Democratic People's Republic of Korea	SK	Slovakia
CU	Cuba	KR	Republic of Korea	SV	El Salvador
CZ	Czechoslovakia	LK	Sri Lanka	TH	Thailand
DE	Germany	LT	Lithuania	TR	Turkey
DK	Djibouti	LU	Luxembourg	TT	Tunisia
DK	Dominican Republic	MK	Montenegro	VE	Venezuela
DK	Djibouti	MU	República de Mauritius	VI	Viet Nam
DK	Dominican Republic	MV	Maldives		
DK	Djibouti	MZ	Mozambique		
DK	Dominican Republic	NC	Nicaragua		
DK	Djibouti	NE	Algeria		
DK	Dominican Republic	NP	Nepal		
DK	Djibouti	NR	Nauru		
DK	Dominican Republic	NU	North Korea		
DK	Djibouti	PY	Paraguay		
DK	Dominican Republic	SL	Sierra Leone		
DK	Djibouti	SR	Saint Lucia		
DK	Dominican Republic	SS	Sudan		
DK	Djibouti	SY	Syria		
DK	Dominican Republic	TD	Togo		
DK	Djibouti	TM	Turkmenistan		
DK	Dominican Republic	TN	Tunisia		
DK	Djibouti	TR	Turkey		
DK	Dominican Republic	TV	Tonga		
DK	Djibouti	UG	Uganda		
DK	Dominican Republic	UY	Uruguay		
DK	Djibouti	VA	Vatican City		
DK	Dominican Republic	VE	Venezuela		
DK	Djibouti	VI	Vietnam		
DK	Dominican Republic	ZW	Zimbabwe		

INTERNATIONAL SEARCH REPORT

International Application No
P.. /US 95/03259

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61L15/22 A61L17/00 A61L25/00 A61L27/00 A61L29/00
A61L31/00 A61L15/42 A61L15/44

According to International Patent Classification (IPC) or to both national classifications and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61L

Documentation searched other than minimum documentation to the extent that such documents are cited in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Character of document, with indication, where appropriate, of the relevant passages	Reference to claim No.
X	WO,A,91 01126 (ATRIX LAB INC) 7 February 1991 see claims; examples 1-11	1-32
X	WO,A,90 03768 (SOUTHERN RES INST) 19 April 1990 see claims	1-32
X	EP,A,0 539 751 (ATRIX LAB INC) 5 May 1993 see examples 1-14	1-3,9-32
X	EP,A,0 537 559 (ATRIX LAB INC) 21 April 1993 see claims	1-3,9-32
X	EP,A,0 560 014 (ATRIX LAB INC) 15 September 1993 see claims; examples	1-3,9-14
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- 'A' document disclosing the general state of the art which is not considered to be of particular relevance
- 'T' earlier document but published on or after the international filing date
- 'L' document which may throw doubts on novelty etc., or which is cited to establish the publication date of another document or other special reasons (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'T' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'T' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, and combination being obvious to a person skilled in the art

'A' document member of the same patent family

1

Date of the actual completion of the international search

22 November 1995

Date of mailing of the international search report

08.12.95

Name and mailing address of the ISA
 European Patent Office, P.O. Box 3018 Potsdamerstr. 2
 D-1000 HV Berlin
 Tel. (+ 31-70) 340-2000, Te. 31 651 000 66,
 Fax (+ 31-70) 340-2016

Authorized officer

ESPINOSA, M

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 95/03259

J. J.

C(C) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Character of document, with reference, where appropriate, of the relevant passage	Reference to claim No.
X	WO,A,92 00718 (ATRIX LAB INC) 23 January 1992 see claims -----	1-3,9-14
X	EP,A,0 159 293 (BATTELLE MEMORIAL INSTITUTE) 23 October 1985 see claims; examples -----	1-3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/03259

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(3)(a) for the following reasons:

1. Claims Nos.: 25, 30-32 because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 25, 30-32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remarks on Payment

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.
PCT/US 95/03259

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9101126	07-02-91	US-A- 5077049 AU-B- 653498 AU-B- 6071890 CA-A- 2063729 DE-D- 69006216 DE-T- 69006216 EP-A- 0484387 ES-T- 2062540 JP-T- 5504941 US-A- 5368859 US-A- 5324519	31-12-91 06-10-94 22-02-91 25-01-91 03-03-94 05-05-94 13-05-92 16-12-94 29-07-93 29-11-94 28-06-94
WO-A-9003768	19-04-90	US-A- 4938763 AU-B- 4501789 AU-B- 5067793 EP-A- 0436667 IL-A- 91850 IL-A- 107393 JP-T- 4503163 US-A- 5278201 US-A- 5340849 US-A- 5278202	03-07-90 01-05-90 17-02-94 17-07-91 30-03-95 29-06-95 11-06-92 11-01-94 23-08-94 11-01-94
EP-A-0539751	05-05-93	US-A- 5324519 AU-A- 2605492 CA-A- 2079831 JP-A- 5305135	28-06-94 29-04-93 29-04-93 19-11-93
EP-A-0537559	21-04-93	AU-A- 2605592 CA-A- 2079830 JP-A- 5286850	22-04-93 16-04-93 02-11-93
EP-A-0560014	15-09-93	AU-B- 3117493 JP-A- 6007423	16-09-93 18-01-94
WO-A-9200718	23-01-92	EP-A- 0489743	17-06-92
EP-A-0159293	23-10-85	JP-A- 60226530	11-11-85